Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check3 days agoChange DetectedThe observed updates are minor UI and content formatting changes that do not alter core study details (eligibility criteria, endpoints, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check10 days agoNo Change Detected
- Check32 days agoChange DetectedUpgraded to version v3.2.0 with a funding-status notice about operational limitations; v3.1.0 was removed. Indicates a maintenance/availability update rather than new content.SummaryDifference4%

- Check39 days agoChange DetectedPage upgraded from v3.0.2 to v3.1.0 with new contact details added; core content and key data types appear unchanged.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the 'Back to Top' control was removed.SummaryDifference0.2%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has updated its facility names and locations, replacing previous terms with more specific identifiers, including the addition of 'cabozantinib' and a new version number.SummaryDifference3%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.